Current nonclinical testing paradigm to allow clinical entry for pharmaceutical drug candidatesjeanfrancoismaisonApr 141 min readRated NaN out of 5 stars.https://pubmed.ncbi.nlm.nih.gov/40090399/
ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosishttps://pubmed.ncbi.nlm.nih.gov/40467521/
Targeting CD117 on hematopoietic stem and progenitor cells impairs CAR T cell activityhttps://pubmed.ncbi.nlm.nih.gov/40450523/
Comments